Sarcoidosis, neurotoxoplasmosis and golimumab therapy

QJM. 2016 Dec;109(12):817-818. doi: 10.1093/qjmed/hcw197. Epub 2016 Dec 22.

Authors

D P Misra¹, K G Chengappa², A Mahadevan³, V K Jain², V S Negi²

Affiliations

¹ From the Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, 605006, India [email protected].
² From the Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, 605006, India.
³ Department of Neuropathology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, 560029, India.

PMID: 28011850
DOI: 10.1093/qjmed/hcw197

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Antibodies, Monoclonal / adverse effects*
Biological Factors / adverse effects*
Humans
Magnetic Resonance Imaging
Male
Sarcoidosis / drug therapy*
Toxoplasmosis, Cerebral / diagnostic imaging*
Toxoplasmosis, Cerebral / etiology
Toxoplasmosis, Cerebral / pathology*

Substances

Antibodies, Monoclonal
Biological Factors
golimumab